McCann Zachary, Zhang Haisu, Mueller Kenneth, Qian Yaoyao, Lane Morgan, Dsouza Rohan, Weil E Jennifer, Ebelt Stefanie, Scovronick Noah, Chang Howard H
Gangarosa Department of Environmental Health, Emory University Rollins School of Public Health, Atlanta, Georgia, USA.
Emory University Nell Hodgson Woodruff School of Nursing, Atlanta, Georgia, USA.
BMJ Public Health. 2025 May 27;3(1):e001703. doi: 10.1136/bmjph-2024-001703. eCollection 2025.
Elevated ambient temperatures increase the risk for acute kidney-related morbidity, and medication use may increase vulnerability to heat exposure. This study examines whether medication use, and combination medication use (ie, polypharmacy), modifies the risk for temperature-related volume depletion (VD) and acute kidney injury (AKI).
This study uses patient-level emergency department (ED) visit data from four Atlanta-area hospitals during the warm season from 2013 to 2019. ED patient-visits who reported a medication were matched with up to five ED patient-visits without the medication. Medications included angiotensin converting enzymes and angiotensin receptor blockers (ACE/ARBs), anti-depressants, anti-convulsants, β-blockers, diuretics, non-steroidal anti-inflammatory drugs and statins. A case-crossover framework is used to estimate associations between daily maximum temperature, medication use and VD/AKI ED visits.
There were 14 635 VD and 18 716 AKI ED visits in this study. For a change in ambient temperature (lags 0-2) from the 50 to 95 percentiles, patients using antidepressants had a higher risk for AKI (OR 1.28, 95% CI 1.08 to 1.52) compared with antidepressant nonusers (1.03, 95% CI 0.95 to 1.12). Polypharmacy analysis indicated that patients taking statins with ACE/ARBs were at an elevated risk for AKI (OR 1.38, 95% CI 1.02 to 1.86) relative to all other groups. This includes patients taking only an ACE/ARB (OR 1.00, 95% CI 0.82 to 1.21), only a statin (OR 1.10, 95% CI 0.90 to 1.33) or neither medication (OR 1.07, 95% CI 0.93 to 1.23).
Results show that both single and combined medication use are associated with elevated risk for VD and AKI during periods of elevated ambient temperature.
环境温度升高会增加急性肾脏相关发病风险,而用药可能会增加受热暴露的易感性。本研究旨在探讨用药情况以及联合用药(即多重用药)是否会改变与温度相关的容量耗竭(VD)和急性肾损伤(AKI)的风险。
本研究使用了2013年至2019年温暖季节期间来自亚特兰大地区四家医院的患者层面的急诊科(ED)就诊数据。报告使用过药物的ED患者就诊病例与最多五例未使用该药物的ED患者就诊病例进行匹配。药物包括血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂(ACE/ARBs)、抗抑郁药、抗惊厥药、β受体阻滞剂、利尿剂、非甾体抗炎药和他汀类药物。采用病例交叉框架来估计每日最高温度、用药情况与VD/AKI急诊就诊之间的关联。
本研究中有14635例VD急诊就诊病例和18716例AKI急诊就诊病例。对于环境温度从第50百分位数到第95百分位数的变化(滞后0至2天),与未使用抗抑郁药的患者相比,使用抗抑郁药的患者发生AKI的风险更高(OR 1.28,95%CI 1.08至1.52),而未使用抗抑郁药的患者发生AKI的风险为1.03(95%CI 0.95至1.12)。多重用药分析表明,与所有其他组相比,同时服用他汀类药物和ACE/ARBs的患者发生AKI的风险升高(OR 1.38,95%CI 1.02至1.86)。这包括仅服用ACE/ARBs的患者(OR 1.00,95%CI 0.82至1.21)、仅服用他汀类药物的患者(OR 1.10,95%CI 0.90至1.33)或两种药物都未服用的患者(OR 1.07,95%CI 0.93至1.23)。
结果表明,在环境温度升高期间,单一用药和联合用药均与VD和AKI的风险升高相关。